All Articles
The Oncology Care Model has made a positive impact on improving access and appropriateness to care while keeping the care patient-centered. Read More ›
Rani Khetarpal shares how models like OCM can be successful. Utilizing an outcomes-based clinical pathway tool and practice transformation are large factors in the success of the models. Read More ›
The future of cancer care delivery is shifting from fee-for-service to a value-based care approach. Read More ›
Results of the prospective phase 2 ATLANT study indicate that lanreotide autogel (LAN) plus temozolomide (TMZ) combination therapy was efficacious and well-tolerated in patients with progressive thoracic neuroendocrine tumors (NETs). Read More ›
Real-world safety data from the US expanded access program of Lu-DOTATATE showed that the safety profile was consistent with that previously described in clinical trials of patients with advanced midgut neuroendocrine tumors (NETs). Read More ›
Findings of a retrospective analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) indicate that peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE may provide clinical benefit and does not significantly impair health-related quality of life (HRQoL). Read More ›
Findings of a retrospective analysis of real-world data indicate that retreatment with 2 extra cycles of peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE provided survival benefit in patients with disease progression after initial PRRT. Read More ›
Subgroup analysis data of the randomized phase 3 SANET-ep trial indicate that the clinical benefits of the multitargeted tyrosine kinase inhibitor surufatinib therapy also extended to major subgroups by Ki67 and primary tumor origin in patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (NETs). Read More ›
Results of a dose-escalation/expansion study in the US population among patients with extrapancreatic and pancreatic neuroendocrine tumors (NETs) indicate promising antitumor activity of the multitargeted tyrosine kinase inhibitor surufatinib, with a safety profile consistent with that previously described in the SANET-ep trial. Read More ›
Post-hoc analytical data of the randomized phase 3 SANET-ep trial indicate that multitargeted tyrosine kinase inhibitor surufatinib therapy was associated with maintenance of health-related quality of life (HRQoL) in previously treated patients with progressive, well-differentiated, advanced extrapancreatic neuroendocrine tumors (NETs). Read More ›